Morphogenesis
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10500 University Center Dr Ste 110, Tamp...Phone Number
(813) 875-6600Website
www.morphogenesis-inc.comRevenue
$18.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Morphogenesis
TuHURA Biosciences, Inc. specializes in developing innovative immune therapies, including their flagship product IMMUNE FX (IFX), an innate immune agonist, and bi-specific immune modulating antibody drug conjugates (ADCs) like TBS-2025. The company is focused on advancing its clinical pipeline, which includes the IFX-2.0 Phase 3 registration trial. TuHURA aims to serve clients in the biopharmaceutical sector, particularly those seeking novel treatments for immune-related conditions. With a commitment to scientific research and development, TuHURA is positioned to make significant contributions to the field of immunotherapy.Explore more
Morphogenesis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Morphogenesis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Morphogenesis recently announced quarterly report
Product Launch: Get notified when Morphogenesis launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Morphogenesis has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Morphogenesis
Website visits: Recent activity has been detected on your website
Morphogenesis, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Morphogenesis has new funding data
Click to see if Morphogenesis had a recent Job posting/layoffs
Check out if Morphogenesis is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Morphogenesis
Compare insights from companies similar to Morphogenesis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Morphogenesis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Morphogenesis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Morphogenesis.
Morphogenesis financials insights
Gather financial insights about Morphogenesis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Private Equity
$2.7M
2018
Series A
$16M
2020
Debt
$350K
Other Financing Round
$2.7M
2021
Debt
$294K
Morphogenesis Tech Stack
A closer look at the technologies used by Morphogenesis
Morphogenesis News & Media
Morphogenesis, with a potential game-changer for skin cancer, raises $2.7 million
The capital raise is occurring as Morphogenesis continues trials on a treatment that's won a key designation from the FDA.Health care innovators 2020: Meet Patricia Lawman, CEO and founder of Morphogenesis
This is an installment in Tampa Bay Business Journal's recognition of some of the region's top health care innovators.Morphogenesis, Inc Celebrates Advancement into Human Clinical Trials
TAMPA, Fla.--(BUSINESS WIRE)--Morphogenesis, Inc., a Tampa, FL-based immunotherapy company celebrates the launch of its first human clinical study in a strategic collaboration with the Cutaneous Oncology Program at Moffitt Cancer Center. After the successful completion of a preclinical research collaboration with Moffitt’s Shari Pilon-Thomas, Ph.D., and Joseph Markowitz, M.D., Ph.D., and subsequent FDA approval for Morphogenesis to move forward with its clinical studies, the Company has embarke
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Morphogenesis
Sign Up For FreeTo access detailed company insights
TuHURA Biosciences, Inc. specializes in developing innovative immune therapies, including their flagship product IMMUNE FX (IFX), an innate immune agonist, and bi-specific immune modulating antibody drug conjugates (ADCs) like TBS-2025. The company is focused on advancing its clinical pipeline, which includes the IFX-2.0 Phase 3 registration trial.... Read More
